In Vitro Assessment of the Biologic Activity of Interferon Beta Formulations Used for the Treatment of Relapsing Multiple Sclerosis

Overview

Journal J Immunoassay Immunochem

Specialty Allergy & Immunology

Date 2014 Mar 25

PMID 24654824

Citations 3

Authors

Carolina Scagnolari

Carla Selvaggi

Emilia Di Biase

Maurizio Fraulo

Fernando Dangond

Guido Antonelli

Affiliations

Soon will be listed here.

Abstract

A new formulation (NF) of subcutaneous (sc) interferon (IFN) β-1a was developed in an attempt to improve injection tolerability and immunogenicity. We compared antiviral and IFNβ-stimulated gene (ISG) activities of IFNβ-1a sc NF with IFNβ-1a sc original formulation and IFNβ-1b sc. When equivalent unit amounts were compared, the IFNβ formulations demonstrated similar antiviral activity and induced similar levels of ISG mRNA. However, on a weight basis (ng/mL), significantly more IFNβ-1b sc was needed to equal the antiviral activity of either IFNβ-1a sc formulation, and both IFNβ-1a sc formulations induced significantly higher levels of ISG mRNA than IFNβ-1b sc.

Citing Articles

Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis.

Ho Y, Woo J, Loke K, Deng L, Too H J Transl Med. 2024; 22(1):463.

PMID: 38750559 PMC: 11097589. DOI: 10.1186/s12967-024-05278-5.

Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.

Brzoska J, von Eick H, Hundgen M Drug Res (Stuttg). 2020; 70(7):291-297.

PMID: 32443163 PMC: 7366041. DOI: 10.1055/a-1170-4395.

Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.

Dicitore A, Grassi E, Borghi M, Gelmini G, Cantone M, Gaudenzi G J Endocrinol Invest. 2017; 40(7):761-770.

PMID: 28247216 DOI: 10.1007/s40618-017-0631-0.

References

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G . Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2008; 15(2):219-28. DOI: 10.1177/1352458508097299. View

Bellomi F, Muto A, Palmieri G, Focaccetti C, Dianzani C, Mattei M . Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol. 2007; 30(3):241-6. View

Pachner A, Narayan K, Price N, Hurd M, Dail D . MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn. 2003; 7(1):17-25. DOI: 10.1007/BF03260016. View

Panitch H, Goodin D, Francis G, Chang P, Coyle P, OConnor P . Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59(10):1496-506. DOI: 10.1212/01.wnl.0000034080.43681.da. View

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002; 359(9316):1453-60. DOI: 10.1016/s0140-6736(02)08430-1. View

Goodin D, Frohman E, Hurwitz B, OConnor P, Oger J, Reder A . Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007; 68(13):977-84. DOI: 10.1212/01.wnl.0000258545.73854.cf. View

Ross C, Clemmesen K, Svenson M, Sorensen P, Koch-Henriksen N, Skovgaard G . Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000; 48(5):706-12. View

Coyle P, Hartung H . Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler. 2002; 8(1):2-9. DOI: 10.1191/1352458502ms735oa. View

Goodin D, Frohman E, Garmany Jr G, Halper J, Likosky W, Lublin F . Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002; 58(2):169-78. DOI: 10.1212/wnl.58.2.169. View

10.

Sorensen P, Deisenhammer F, Duda P, Hohlfeld R, Myhr K, Palace J . Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005; 12(11):817-27. DOI: 10.1111/j.1468-1331.2005.01386.x. View

11.

Gonzalez-Andrade F, Alcaraz-Alvarez J . Disease-modifying therapies in relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2010; 6:365-73. PMC: 2938285. DOI: 10.2147/ndt.s11079. View

12.

Scagnolari C, Zingariello P, Vecchiet J, Selvaggi C, Racciatti D, Taliani G . Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J. 2010; 7:311. PMC: 2996368. DOI: 10.1186/1743-422X-7-311. View

13.

Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M . The Rebif new formulation story: it's not trials and error. Drugs R D. 2007; 8(6):335-48. DOI: 10.2165/00126839-200708060-00002. View

14.

. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001; 56(12):1628-36. DOI: 10.1212/wnl.56.12.1628. View

15.

Scagnolari C, Antonelli G . Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Expert Opin Biol Ther. 2013; 13(5):693-711. DOI: 10.1517/14712598.2013.764409. View

16.

Basu M, Maitra R, Xiang Y, Meng X, Banerjee A, Bose S . Inhibition of vesicular stomatitis virus infection in epithelial cells by alpha interferon-induced soluble secreted proteins. J Gen Virol. 2006; 87(Pt 9):2653-2662. DOI: 10.1099/vir.0.82039-0. View

17.

Meager A, Das R . Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta. J Immunol Methods. 2005; 306(1-2):1-15. DOI: 10.1016/j.jim.2005.08.007. View

18.

Runkel L, Meier W, Pepinsky R, Karpusas M, Whitty A, KIMBALL K . Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res. 1998; 15(4):641-9. DOI: 10.1023/a:1011974512425. View

19.

. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995; 45(7):1277-85. View

20.

Samuel C . Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology. 2011; 411(2):180-93. PMC: 3057271. DOI: 10.1016/j.virol.2010.12.004. View